An interventional study of Robust RB-KRC-HMD-U01 with WOLFGANG HD18M and Nikkiso DBB-EXA ES with Purifier H180 in Hemodialysis and End Stage Chronic Renal Failure, sponsored by Bethesda Hospital Yogyakarta. Completed at 1 site in Indonesia. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-11-13.
Sponsored by Bethesda Hospital Yogyakarta · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Hemodialysis uses a machine and a filter to remove waste products such as urea from the blood. This study compared a new dialysis system with the system already in use at Bethesda Hospital in Yogyakarta, Indonesia. The main question was whether the new system could deliver a dialysis dose close to that of the established system during a single treatment.
Adults receiving dialysis twice a week were scheduled for two treatments with the new system, followed by two with the established system. The researchers measured blood urea before and after each treatment to estimate the dialysis dose. They also measured changes in other blood substances and recorded adverse events.
This prospective, single-center, nonrandomized study enrolled adults aged 18 to 75 years who had received maintenance hemodialysis for at least three months at Bethesda Hospital in Yogyakarta, Indonesia. All participants followed a twice-weekly dialysis schedule and had arteriovenous fistula access.
Each participant was scheduled for four sessions over two weeks. The first two sessions used the Robust RB-KRC-HMD-U01 machine with the WOLFGANG HD18M dialyzer. The next two used the Nikkiso DBB-EXA ES machine with the Purifier H180 dialyzer. Within each participant, prescribed treatment duration, blood flow rate, and dialysate flow rate were matched across periods. Ultrafiltration was individualized according to clinical need. Both the machine and dialyzer changed between periods, and all participants received the systems in the same order without a washout. The design therefore compared the two complete systems and could not separate their effects from treatment order or distinguish the contribution of the machine from that of the dialyzer.
The primary outcome was per-session single-pool Kt/V (spKt/V), a measure of urea-based dialysis dose calculated using the second-generation Daugirdas equation. The two session values were averaged within each participant and treatment period. The planned noninferiority comparison used the paired difference in spKt/V, calculated as new system minus established system, with a prespecified margin of -0.15.
Other assessments included the per-session urea reduction ratio, serum chemistry, blood counts, blood pressure, body weight, and achieved ultrafiltration. For the exploratory beta-2-microglobulin outcome, the intended sampling times were immediately before the first session and immediately after the second session of each period. The difference between these concentrations represented the change over two sessions. Adverse events were documented during the study, and serious adverse events were summarized according to the system each participant had received.
2,112 studies on the registry are indexed under Kidney Failure, Chronic; 274 are open to participants now.
This study's enrollment of 20 is below the median of 57 across 1,572 interventional studies indexed under Kidney Failure, Chronic.
Browse Kidney Failure, Chronic studies →This is the only study on the registry with Bethesda Hospital Yogyakarta as lead sponsor.
Compared within Kidney Failure, Chronic, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Renal Insufficiency, Chronic. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Device: Robust RB-KRC-HMD-U01 with WOLFGANG HD18M · Device: Nikkiso DBB-EXA ES with Purifier H180
Two successive hemodialysis sessions with this machine and its single-use dialyzer in period 1
Two successive hemodialysis sessions with this machine and its single-use dialyzer in period 2
Single-pool Kt/V per dialysis session
Unitless urea-based dose estimated by the second-generation Daugirdas equation from pre- and postdialysis urea and session data. The two session values were averaged within participant and period.
Time frame: Before and after each of four scheduled dialysis sessions, two per period, over approximately two weeks.
Urea reduction ratio
Percentage fall in blood urea, calculated as 100 × (predialysis urea - postdialysis urea) / predialysis urea
Time frame: Before and after each scheduled dialysis session in each two-session period, over approximately two weeks
Two-session change in serum beta-2-microglobulin concentration (mg/L)
End-of-period minus start-of-period concentration
Time frame: Immediately before session 1 and intended immediately after session 2 in each period, over approximately two weeks.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No — The study team does not plan to share individual participant data. The available study records include aggregate results, but a complete, verified dataset linking each participant's measurements across the two treatment periods is unavailable for release. The study findings will be reported in aggregate.
Ran from Apr 2026 to primary completion in Apr 2026, 0 months.
Of 349 non-industry interventional studies with no phase under Kidney Failure, Chronic, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 47. This study's 0 months is below that.
Counting every sponsor, half of 427 studies reached it within 22 months; a quarter within 8 and three quarters within 45.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.